Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue

Journal of Neuro-Oncology

Volumn 86, Issue 2, 2008, Pages 123-132

  Joshi, Shailendra ^a   Wang, Mei ^a   Etu, Joshua J ^a   Suckow, Raymond F ^b   Cooper, Thomas B ^b   Feinmark, Steven J ^a   Bruce, Jeffrey N ^a   Fine, Robert L ^a  

^a Columbia University ^*  (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Chemotherapy; Intraarterial; Pharmacokinetics; Regional

Indexed keywords

ADENOSINE; CARMUSTINE; ESMOLOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; BALLOON CATHETER; BLOOD BRAIN BARRIER; BOLUS INJECTION; BRAIN BLOOD FLOW; BRAIN INJURY; BRAIN PERFUSION; BRAIN TISSUE; CAROTID ARTERY; CONTROLLED STUDY; DILUTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; GLIOBLASTOMA; HEART ARREST; HISTOPATHOLOGY; HYPERVENTILATION; HYPOTENSION; HYPOTHERMIA; HYPOTHESIS; MALE; NONHUMAN; RABBIT;

ADENOSINE; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; CARMUSTINE; CAROTID ARTERIES; CEREBROVASCULAR CIRCULATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; INTRACRANIAL HYPOTENSION; ISCHEMIC ATTACK, TRANSIENT; MALE; PROPANOLAMINES; RABBITS; STATISTICS, NONPARAMETRIC; VASODILATOR AGENTS;

EID: 37249025132     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9450-z     Document Type: Article

References (32)

1. Senger D, Cairncross JG, Forsyth PA (2003) Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype?[see comment]. Cancer J 9(3):214-221
2. Wemmert S, Ketter R, Rahnenfuhrer J, Beerenwinkel N, Strowitzki M, Feiden W, Hartmann C, Lengauer T, Stockhammer F, Zang KD, Meese E, Steudel WI, von Deimling A, Urbschat S (2005) Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7(10):883-893
3. Sampath P, Rhines LD, DiMeco F, Tyler BM, Park MC, Brem H et al (2006) Interstitial docetaxel (Taxotere), carmustine and combined interstitial therapy: A novel treatment for experimental malignant glioma. J Neurooncol 80(1):9-17
4. Hall WA, Rustamzadeh E, Asher AL (2003) Convection-enhanced delivery in clinical trials. Neurosurg Focus 14(2):e2
5. Neuwelt EA, Glasberg M, Frenkel E, Barnett P, (1983) Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 14(3):316-324
6. Dedrick RL (1988) Arterial drug infusion: Pharmacokinetic problems and pitfalls. J Natl Cancer Inst 80(2):84-89
7. Pile-Spellman J (1996) Endovascular therapeutic neuroradiology (Chapter 18). In: Taveras JM (ed) Neuroradiology, 3rd edn. Williams and Wilkins, Baltimore, pp 1045-1179
8. Joshi S, Wang M, Etu J, Nishanian EV (2006) Comparison of intracarotid anesthetics for EEG silence. J Neurosurg Anesthesiol 18(2):112-118
9. Joshi S, Wang M, Etu JJ, Nishanian EV, Pile-Spellman J (2006) Cerebral blood flow affects dose requirements of intracarotid propofol for electrocerebral silence. Anesthesiology 104(2):290-298, discussion 5A
10. Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E III (1986) Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 70(7):877-880
11. Lee JS, Hamilton MG, Zabramski JM (1994) Variations in the anatomy of the rabbit cervical carotid artery. Stroke 25(2):501-503
12. Stewart DJ, Grahovac Z, Hugenholtz H, DaSilva V, Richard MT, Benoit B, Belanger G, Russell N (1993) Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. J Neurooncol 17(1):71-79
13. Stewart DJ, Dahrouge S, Wee M, Aitken S, Hugenholtz H (1995) Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol 24(2):189-194
14. Hassenbusch SJ, Anderson JH, Colvin OM (1996) Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions. J Neurooncol 30(1):7-18
15. Joshi S, Wang M, Hartl R (2004) Retinal Discoloration test. J Cereb Blood Flow Metab 24(3):305-308
16. Joshi S, Wang M, Etu JJ, Pile-Spellman J (2006) Bolus configuration affects dose requirements of intracarotid propofol for electroencephalographic silence. Anesth Analg 102(6):1816-1822
17. Joshi S, Wang M, Etu JJ, Pile-Spellman J. (2005) Reducing cerebral blood flow increases the duration of electroencephalographic silence by intracarotid thiopental. Anesth Analg 101(3):851-858
18. Hassenbusch SJ, Colvin OM, Anderson JH (1995) Determination of nitrosourea compounds in brain tissue by gas chromatography and electron capture detection. J Pharm Sci 84(7):840-842
19. Supko JG, Phillips LR, Malspeis L (1996) Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma. J Chromatogr B Biomed Appl 677(2):351-362
20. Hartl R et al (2005) Pial arterial response to topical verapamil in acute closed cranial windows in rabbits. Anesth Analg 100(4):1140-1146
21. Wang M, Joshi S (2007) Electrocerebral silence after intracarotid propofol is a function of transit time. Anesth Analg 104(6):1498-1503
22. Fenstermacher J, Gazendam J (1981) Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 65(Suppl 2):27-37
23. Allman JM (1999) The evolution of big brains, 1st edn. Evolving brains in Scientific American Library, New York, pp 158-208
24. Saris SC, Blasberg RG, Carson RE, deVroom HL, Lutz R, Dedrick RL, Pettigrew K, Chang R, Doppman J, Wright DC et al (1991) Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 74(5):763-772
25. Saris SC, Shook DR, Blasberg RG, Dedrick RL, Doppman JL, Bankiewicz KS, Blacklock JB, Oldfield EH (1987) Carotid artery mixing with diastole-phased pulsed drug infusion. J Neurosurg 67(5):721-725
26. Lutz RJ, Dedrick RL, Boretos JW, Oldfield EH, Blacklock JB, Doppman JL (1986) Mixing studies during intracarotid artery infusions in an in vitro model. J Neurosurgery 64(2):277-283
27. Pile-Spellman J, Young WL, Joshi S, Duong H, Vang MC, Hartmann A, Kahn RA, Rubin DA, Prestigiacomo CJ, Ostapkovich ND (1999) Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: Technical case report. Neurosurgery 44(4):881-886.
28. Hashimoto T, Young WL, Aagaard BD, Joshi S, Ostapkovich ND, Pile-Spellman J (2000) Adenosine-induced ventricular asystole to induce transient profound systemic hypotension in patients undergoing endovascular therapy: Dose-response characteristics. Anesthesiology 93(4):998-1001
29. Smith BH, Vaughan M, Greenwood MA, Kornblith PL, Robinson A, Shitara N, McKeever PE (1983) Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines. J Neurooncol 1(3):237-248
30. Gobin YP, Cloughesy TF, Chow KL, Duckwiler GR, Sayre JW, Milanese K, Vinuela F (2001) Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 218(3):724-732
31. Oldfield EH, Dedrick RL, Chatterji DC, Yeager RL, Girton ME, Kornblith PL, Doppman JL (1985) Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey. Cancer Treat Rep 69(3):293-303
32. Davis MR, Kassahun K, Jochheim CM, Brandt KM, Baillie TA (1993) Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N, N′-bis(2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro. Chemical Res Toxicol 6(3):376-383